



Council of the  
European Union

Brussels, 16 November 2020  
(OR. en)

12603/20

CORDROGUE 62  
SAN 389

**NOTE**

---

From: General Secretariat of the Council  
To: Delegations

---

Subject: EU Statement on the occasion of the 3rd Intersessional Meeting of the 63rd Session of the Commission on Narcotic Drugs, Vienna, 19-21 October 2020

- Thematic session 2: The adverse health consequences of and risks associated with new psychoactive substances have reached alarming levels

---

Delegations will find in the annex the EU statement for Thematic Session 2 of the 3rd Intersessional Meeting of the 63rd Session of the Commission on Narcotic Drugs, as it was expressed on behalf of the EU in Vienna on 19-21 October 2020.



**European Union Statement  
on the occasion of the 3rd Intersessional Meeting  
of the 63rd Session of the Commission on Narcotic Drugs,  
Vienna, 19-21 October 2020**

**Thematic session 2: The adverse health consequences of and risks associated with  
new psychoactive substances have reached alarming levels**

I have the honour to speak on behalf of the European Union and its Member States. The following countries align themselves with this statement: Turkey<sup>§</sup>, the Republic of North Macedonia<sup>\*</sup>, Montenegro<sup>\*</sup>, Serbia<sup>\*</sup>, Albania<sup>\*</sup>, Bosnia and Herzegovina<sup>\*</sup>, Ukraine, Iceland<sup>+</sup>, Norway<sup>+</sup>, the Republic of Moldova and Georgia.

Mr. Chair, Excellencies, Ladies and Gentlemen,

1. According to UNODC's World Drug Report 2020, roughly 500 new psychoactive substances (NPS) are found on the national markets of UN Member States each year. While the overall number of NPS has stabilised, their types have changed. An increasing number of NPS are opioids, including many fentanyl analogues, but some also from diverse and new groups. These synthetic opioids have proved both potent and harmful, fuelling overdose deaths in some regions of the world.

---

<sup>§</sup> Candidate Country

<sup>\*</sup> Candidate Countries the Republic of North Macedonia, Montenegro, Serbia and Albania as well as potential Candidate Country Bosnia and Herzegovina continue to be part of the Stabilisation and Association Process.

<sup>+</sup> Iceland and Norway are members of the EFTA and of the European Economic Area

2. While many NPS tend to be transient on the drug markets, patterns of NPS use have been observed among marginalised and vulnerable groups - in particular the use of synthetic cannabinoids. This is true also for Europe. In a 2016 study of the EMCDDA, the EU's Drugs Agency, over two thirds of countries reported that their use by high-risk drug users resulted in health concerns. In particular, the use of synthetic cathinones ('bath salts') by people who use and inject opioids and stimulants has been linked to severe health and social problems. In addition, the smoking of synthetic cannabinoids in marginalised populations, including homeless people and prisoners, has been identified as a problem in a number of European countries.

Mr. Chair,

3. According to the European Drug Report 2020, new psychoactive substances (NPS) have become a more persistent problem. Over the past three years, NPS have been detected for the first time in Europe at the rate of around one per week. 53 substances were detected for the first time in 2019. The EU's early warning system is monitoring around 800 new psychoactive substances, of which more than half are available on the European drug market in any given year.

4. The international community has reacted in a timely manner to assess the harms caused by NPS and to schedule those that warrant international control. The EU early warning system and the UNODC early warning advisory help to keep the international community abreast of developments. Both, the European Union and the Commission on Narcotic Drugs, have acted swiftly in recent years to schedule the most harmful new psychoactive substances. The European Union adopted new legislation in 2017 to speed up the process to ban NPS. All this helped reducing the growth in new psychoactive substances.

5. The overall consumption levels of new psychoactive substances are still relatively low in Europe and few people currently enter treatment in Europe for problems associated with the use of new psychoactive substances.

6. Nevertheless, NPS continue to represent a serious threat to health and security due to the number of potent opioids, synthetic cannabinoids and benzodiazepines appearing on the market and the associated health emergencies and deaths. It is our responsibility to continue to address these problems, while paying special attention to young consumer groups as well as vulnerable and socially disadvantaged groups, including the homeless and prison populations.

7. We are convinced that our full attention needs to focus on further strengthening national, regional and international actions in order to address the challenges of new psychoactive substances, including their adverse health consequences. We need to develop appropriate measures, including early warning mechanisms and appropriate prevention and treatment models. And we have to support the scientific evidence-based review and scheduling of the most prevalent, persistent and harmful substances.

8. The EU's 3-step-approach of early warning, risk assessment and control measures is part of the EU's evidence-based, integrated, balanced and multidisciplinary approach to drugs policy, aiming to protect public health.

9. We reaffirm our commitment to promoting and protecting health, including access to treatment, safety and the well-being of all humanity.

Thank you for your attention.

---